Johnson & Johnson | Q2 2025: Revenue up 5.8%, net profit surprises

In 2025, healthcare giant Johnson & Johnson continues to show why it holds a reputation as one of the most respected corporations in the industry. The company remains a leader in innovation in areas such as oncology, neurology and cardiology, while its MedTech division sets the pace in the development of advanced devices. Despite intensifying competition and dynamic market conditions, J&J has repeatedly demonstrated its ability to come up with new therapies and technologies that are finding traction not only in the U.S. but around the world.

At the same time, however, the flip side of global greatness is becoming increasingly apparent. The company continues to face extensive legal challenges related to talc-containing products, and lawsuits are beginning to pile up with new intensity. The number of lawsuits has increased significantly over the summer months, with courts refusing to settle collectively, thereby prolonging the process and increasing the risk of high costs. Johnson &…